1
|
Lorenzana GP, Figueiró HV, Kaelin CB, Barsh GS, Johnson J, Karlsson E, Morato RG, Sana DA, Cullen L, May JA, Moraes EA, Kantek DLZ, Silveira L, Murphy WJ, Ryder OA, Eizirik E. Whole-genome sequences shed light onto the demographic history and contemporary genetic erosion of free-ranging jaguar (Panthera onca) populations. J Genet Genomics 2021; 49:77-80. [PMID: 34767971 DOI: 10.1016/j.jgg.2021.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 10/20/2021] [Accepted: 10/21/2021] [Indexed: 10/19/2022]
Affiliation(s)
- Gustavo P Lorenzana
- Pontifical Catholic University of Rio Grande do Sul, PUCRS. School of Health and Life Sciences, Porto Alegre, RS, 90619, Brazil
| | - Henrique V Figueiró
- Pontifical Catholic University of Rio Grande do Sul, PUCRS. School of Health and Life Sciences, Porto Alegre, RS, 90619, Brazil
| | | | - Gregory S Barsh
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, 35806, USA
| | - Jeremy Johnson
- Vertebrate Genome Biology, Broad Institute, Cambridge, MA, 02142, USA
| | - Elinor Karlsson
- Vertebrate Genome Biology, Broad Institute, Cambridge, MA, 02142, USA
| | | | - Dênis A Sana
- PPG Biologia Animal, Instituto de Biociências, UFRGS, Porto Alegre, RS, 90650, Brazil
| | - Laury Cullen
- Instituto de Pesquisas Ecológicas, Teodoro Sampaio, SP, 19280, Brazil
| | - Joares A May
- UniSul, Tubarão, SC, 88704, Brazil; Instituto Pró-Carnívoros, Atibaia, SP, 12945, Brazil
| | | | | | - Leandro Silveira
- Instituto Onça-pintada - Jaguar Conservation Fund, Mineiros, GO, 75830, Brazil
| | | | - Oliver A Ryder
- San Diego Zoo Institute for Conservation Research, San Diego, CA, 92027, USA
| | - Eduardo Eizirik
- Pontifical Catholic University of Rio Grande do Sul, PUCRS. School of Health and Life Sciences, Porto Alegre, RS, 90619, Brazil; Instituto Pró-Carnívoros, Atibaia, SP, 12945, Brazil.
| |
Collapse
|
2
|
Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of Ticlopidine Administered to Healthy Volunteers on Platelet Function in Whole Blood. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649932] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryTiclopidine is thought to be a selective inhibitor of ADP-induced platelet function. Here we have investigated the effects of ticlopidine on platelet function in whole blood induced by ADP and by other platelet agonists. Whole blood was used because it was considered that ADP derived from red cells might act synergistically with other platelet agonists to enhance platelet responses, and that ticlopidine might interfere with this process. Measurements were performed using blood from 16 healthy volunteers before ticlopidine administration, after taking ticlopidine 250 mg daily for 10 days, after taking ticlopidine 250 mg twice daily for a further 10 days, and after 14 days off treatment.Ticlopidine proved to be a very effective inhibitor of the platelet aggregation induced by ADP; it was most effective in enhancing the reversibility of the aggregation response. The drug modestly but significantly reduced streptokinase, adrenaline, collagen, sodium arachidonate, PAF and U46619 – induced platelet aggregation. The drug significantly reduced the extent of the release reaction (14C-5HT release) induced by ADP, streptokinase, PAF, ristocetin and sodium arachidonate, and also reduced the extent of the synergistic 14C-5HT release induced by combinations of ADP and PAF, ADP and adrenaline and PAF and adrenaline.The various inhibitory effects of ticlopidine were evident after treatment with 250 mg daily but were more pronounced after 250 mg twice daily. All values had returned to normal after 14 days off treatment. Ticlopidine had no effect on serum thromboxane B2 production nor on several parameters of coagulation and fibrinolysis.We conclude that ticlopidine is an effective inhibitor of ADP-induced platelet aggregation and also the platelet aggregation and 14C-5HT release induced in whole blood by a number of platelet agonists and combinations of agonists. These latter effects are probably mainly via a selective effect on ADP. The inhibitory effects of the drug are dose-related.
Collapse
Affiliation(s)
- S Heptinstall
- The Cardiovascular Medicine, University Hospital, Queen’s Medical Centre, Nottingham, U.K
| | - J A May
- The Cardiovascular Medicine, University Hospital, Queen’s Medical Centre, Nottingham, U.K
| | - J R Glenn
- The Cardiovascular Medicine, University Hospital, Queen’s Medical Centre, Nottingham, U.K
| | - H M Sanderson
- The Cardiovascular Medicine, University Hospital, Queen’s Medical Centre, Nottingham, U.K
| | | | - R G Wilcox
- The Cardiovascular Medicine, University Hospital, Queen’s Medical Centre, Nottingham, U.K
| |
Collapse
|
3
|
Morato RG, Thompson JJ, Paviolo A, de La Torre JA, Lima F, McBride RT, Paula RC, Cullen L, Silveira L, Kantek DLZ, Ramalho EE, Maranhão L, Haberfeld M, Sana DA, Medellin RA, Carrillo E, Montalvo V, Monroy-Vilchis O, Cruz P, Jacomo AT, Torres NM, Alves GB, Cassaigne I, Thompson R, Saens-Bolanos C, Cruz JC, Alfaro LD, Hagnauer I, da Silva XM, Vogliotti A, Moraes MFD, Miyazaki SS, Pereira TDC, Araujo GR, da Silva LC, Leuzinger L, Carvalho MM, Rampin L, Sartorello L, Quigley H, Tortato F, Hoogesteijn R, Crawshaw PG, Devlin AL, May JA, de Azevedo FCC, Concone HVB, Quiroga VA, Costa SA, Arrabal JP, Vanderhoeven E, Di Blanco YE, Lopes AMC, Widmer CE, Ribeiro MC. Jaguar movement database: a GPS-based movement dataset of an apex predator in the Neotropics. Ecology 2018; 99:1691. [DOI: 10.1002/ecy.2379] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 03/31/2018] [Accepted: 04/11/2018] [Indexed: 11/06/2022]
|
4
|
Morato RG, Stabach JA, Fleming CH, Calabrese JM, De Paula RC, Ferraz KMPM, Kantek DLZ, Miyazaki SS, Pereira TDC, Araujo GR, Paviolo A, De Angelo C, Di Bitetti MS, Cruz P, Lima F, Cullen L, Sana DA, Ramalho EE, Carvalho MM, Soares FHS, Zimbres B, Silva MX, Moraes MDF, Vogliotti A, May JA, Haberfeld M, Rampim L, Sartorello L, Ribeiro MC, Leimgruber P. Space Use and Movement of a Neotropical Top Predator: The Endangered Jaguar. PLoS One 2016; 11:e0168176. [PMID: 28030568 PMCID: PMC5193337 DOI: 10.1371/journal.pone.0168176] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2016] [Accepted: 11/25/2016] [Indexed: 11/19/2022] Open
Abstract
Accurately estimating home range and understanding movement behavior can provide important information on ecological processes. Advances in data collection and analysis have improved our ability to estimate home range and movement parameters, both of which have the potential to impact species conservation. Fitting continuous-time movement model to data and incorporating the autocorrelated kernel density estimator (AKDE), we investigated range residency of forty-four jaguars fit with GPS collars across five biomes in Brazil and Argentina. We assessed home range and movement parameters of range resident animals and compared AKDE estimates with kernel density estimates (KDE). We accounted for differential space use and movement among individuals, sex, region, and habitat quality. Thirty-three (80%) of collared jaguars were range resident. Home range estimates using AKDE were 1.02 to 4.80 times larger than KDE estimates that did not consider autocorrelation. Males exhibited larger home ranges, more directional movement paths, and a trend towards larger distances traveled per day. Jaguars with the largest home ranges occupied the Atlantic Forest, a biome with high levels of deforestation and high human population density. Our results fill a gap in the knowledge of the species' ecology with an aim towards better conservation of this endangered/critically endangered carnivore-the top predator in the Neotropics.
Collapse
Affiliation(s)
- Ronaldo G. Morato
- Centro Nacional de Pesquisa e Conservação de Mamíferos Carnívoros, Instituto Chico Mendes de Conservação da Biodiversidade, Atibaia, São Paulo, Brazil
- Conservation Ecology Center, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia, United States of America
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
| | - Jared A. Stabach
- Conservation Ecology Center, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia, United States of America
| | - Chris H. Fleming
- Conservation Ecology Center, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia, United States of America
| | - Justin M. Calabrese
- Conservation Ecology Center, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia, United States of America
| | - Rogério C. De Paula
- Centro Nacional de Pesquisa e Conservação de Mamíferos Carnívoros, Instituto Chico Mendes de Conservação da Biodiversidade, Atibaia, São Paulo, Brazil
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
| | - Kátia M. P. M. Ferraz
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
- Escola Superior de Agricultura “Luiz de Queiroz”, Universidade de São Paulo, Piracicaba, Brazil
| | - Daniel L. Z. Kantek
- Estação Ecológica Taiamã, Instituto Chico Mendes de Conservação da Biodiversidade, Cáceres, Mato Grosso, Brazil
| | - Selma S. Miyazaki
- Estação Ecológica Taiamã, Instituto Chico Mendes de Conservação da Biodiversidade, Cáceres, Mato Grosso, Brazil
| | - Thadeu D. C. Pereira
- Estação Ecológica Taiamã, Instituto Chico Mendes de Conservação da Biodiversidade, Cáceres, Mato Grosso, Brazil
| | - Gediendson R. Araujo
- Departamento de Medicina Veterinária, Universidade Federal de Viçosa, Viçosa, Minas Gerais, Brazil
| | - Agustin Paviolo
- Instituto de Biología Subtropical, Universidad Nacional de Misiones and CONICET, Puerto Iguazú, Argentina
| | - Carlos De Angelo
- Instituto de Biología Subtropical, Universidad Nacional de Misiones and CONICET, Puerto Iguazú, Argentina
| | - Mario S. Di Bitetti
- Instituto de Biología Subtropical, Universidad Nacional de Misiones and CONICET, Puerto Iguazú, Argentina
| | - Paula Cruz
- Instituto de Biología Subtropical, Universidad Nacional de Misiones and CONICET, Puerto Iguazú, Argentina
| | - Fernando Lima
- IPÊ – Instituto de Pesquisas Ecológicas, Nazaré Paulista, São Paulo, Brazil
- Laboratório de Ecologia Espacial e Conservação, Instituto de Biociências, Univesidade Estadual de São Paulo, Rio Claro, São Paulo, Brazil
| | - Laury Cullen
- IPÊ – Instituto de Pesquisas Ecológicas, Nazaré Paulista, São Paulo, Brazil
| | - Denis A. Sana
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
- Programa de Pós-graduação em Ecologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
| | - Emiliano E. Ramalho
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
- Instituto de Desenvolvimento Sustentável Mamirauá, Tefé, Amazonas, Brazil
| | - Marina M. Carvalho
- Instituto de Defesa e Preservação dos Felídeos Brasileiros, Corumbá de Goiás, Goiás, Brazil
| | - Fábio H. S. Soares
- Instituto de Defesa e Preservação dos Felídeos Brasileiros, Corumbá de Goiás, Goiás, Brazil
| | - Barbara Zimbres
- Programa de Pós Graduação em Zoologia, Instituto de Ciências Biológicas, Universidade de Brasília, Federal District, Brazil
| | - Marina X. Silva
- Projeto Carnívoros do Iguaçu, Parque Nacional do Iguaçu, Instituto Chico Mendes de Conservação da Biodiversidade, Foz do Iguaçu, Paraná, Brazil
| | - Marcela D. F. Moraes
- Projeto Carnívoros do Iguaçu, Parque Nacional do Iguaçu, Instituto Chico Mendes de Conservação da Biodiversidade, Foz do Iguaçu, Paraná, Brazil
| | - Alexandre Vogliotti
- Instituto Pró-Carnívoros, Atibaia, São Paulo, Brazil
- Universidade Federal da Integração Latino-Americana, Foz do Iguaçu, Paraná, Brazil
| | - Joares A. May
- Projeto Onçafari Miranda, Mato Grosso do Sul, Brazil
| | | | - Lilian Rampim
- Projeto Onçafari Miranda, Mato Grosso do Sul, Brazil
| | | | - Milton C. Ribeiro
- Laboratório de Ecologia Espacial e Conservação, Instituto de Biociências, Univesidade Estadual de São Paulo, Rio Claro, São Paulo, Brazil
| | - Peter Leimgruber
- Conservation Ecology Center, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, Virginia, United States of America
| |
Collapse
|
5
|
Fox SC, May JA, Johnson A, Hermann D, Strieter D, Hartman D, Heptinstall S. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers. Platelets 2012; 24:392-400. [PMID: 22866894 DOI: 10.3109/09537104.2012.704648] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. DG-041 is an EP3 antagonist in the early stage of clinical development. Here, we quantitated effects on platelet function of DG-041 in-vitro and ex-vivo after administration to man when given alone and concomitantly with clopidogrel or clopidogrel and aspirin. With its unique mechanism of action, it was anticipated that DG-041 would potentiate inhibition of platelet function when given in combination with clopidogrel without materially increasing bleeding time. Initially, in-vitro studies were performed to determine inhibitory effects of DG-041 (3 µM) used alone or in combination with the P2Y12 antagonist cangrelor (1 µM), both without and with aspirin (100 µM). Platelet aggregation and P-selectin expression were measured in whole blood (n = 10) following stimulation with the thromboxane A2 (TXA2) mimetic U46619 (0.3 or 1 µM) in combination with either the EP3 agonist sulprostone (0.1 µM), or PGE2 (1 µM). DG-041 alone partially inhibited platelet function in-vitro, as did cangrelor. Addition of both DG-041 and cangrelor in combination provided significantly greater inhibition. An ex-vivo study was then performed using the same experimental approaches. This clinical study was a prospective, randomised, blinded (for DG-041/matching placebo), blocked, crossover study designed to compare the effects of DG-041, clopidogrel, or the combination of DG-041 with either clopidogrel or clopidogrel and aspirin. Healthy volunteers (n = 42) were randomly assigned to receive no background treatment, clopidogrel (300 mg loading dose plus 75 mg daily) or clopidogrel and aspirin (75 mg daily) for 10 days alongside DG-041 (200 mg twice daily) or placebo for 5 days, crossed over to placebo or DG-041 for the next 5 days. Platelet effects and bleeding time were measured at baseline, days 5 and 10. DG-041 partially inhibited platelet function ex-vivo, as did clopidogrel, while administration of both DG-041 and clopidogrel provided significantly greater inhibition. Administration of DG-041 alone did not increase bleeding time, and did not significantly affect the increased bleeding time seen with clopidogrel or clopidogrel with aspirin. Using these experimental approaches, the antiplatelet effects of DG-041 and a P2Y12 antagonist used alone and in combination can be determined both in-vitro and ex-vivo. Results show inhibitory effects of DG-041 on platelet function acting via EP3 receptor blockade, confirmed to be additional to those brought about by P2Y12 blockade. In both in-vitro and ex-vivo studies, aspirin neither promoted nor negated the effects of the other drugs.
Collapse
Affiliation(s)
- S C Fox
- Department of Cardiovascular Medicine, School of Clinical Sciences, University of Nottingham, Nottingham, UK.
| | | | | | | | | | | | | |
Collapse
|
6
|
Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009; 20:250-9. [PMID: 19440925 DOI: 10.1080/09537100902912451] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
There is great interest in assessing the efficacy of treatment with clopidogrel and aspirin in patients with cardiovascular disease using procedures that can be used in a remote setting. Here we have established methods to assess the effects of clopidogrel and aspirin on platelets based on measurements of platelet P-selectin. Platelets were stimulated in whole blood by adding the combination of adenosine diphosphate and the TXA(2) mimetic U46619 (ADP/U4, designed to assess P2Y(12) inhibition) or the combination of arachidonic acid and epinephrine (AA/Epi, designed to assess COX-1 inhibition). The stimulated samples were then fixed using a fixative solution that provides stability for at least 9 days, and sent to a central laboratory for analysis of P-selectin by flow cytometry. Measurements were performed in blood from healthy volunteers and patients with cardiovascular disease. The inhibitory effects of clopidogrel and aspirin were assessed ex vivo and the effects of the direct acting P2Y(12) antagonist cangrelor and aspirin were assessed in vitro. Measurements of platelet aggregation were also performed for comparison. In healthy volunteers clopidogrel ex vivo and cangrelor in vitro markedly inhibited P-selectin expression induced by ADP/U4. Aspirin did not inhibit and did not interfere with the effects of clopidogrel or cangrelor using this test. There was very little overlap of results obtained in the absence and presence of clopidogrel or cangrelor. In contrast, over half of 42 patients with cardiovascular disease did not respond well to clopidogrel treatment, although cangrelor was still effective. Aspirin markedly inhibited P-selectin expression induced by AA/Epi. Clopidogrel had much less effect and did not interfere with the effects of aspirin. There was no overlap of results obtained in the absence and presence of aspirin. Aspirin provided near-complete inhibition in 29 of 30 patients with cardiovascular disease. Aggregometry measurements agreed well with the P-selectin data obtained ex vivo following both clopidogrel and aspirin treatment. It is concluded that measurements of P-selectin performed on fixed blood samples following platelet stimulation in whole blood in a remote setting can be used effectively to monitor the effects of clopidogrel and aspirin.
Collapse
Affiliation(s)
- S C Fox
- Cardiovascular Medicine, Queens Medical Centre, Nottingham, UK.
| | | | | | | | | |
Collapse
|
7
|
May JA, Ratan H, Glenn JR, Lösche W, Spangenberg P, Heptinstall S. GPIIb-IIIa antagonists cause rapid disaggregation of platelets pre-treated with cytochalasin D. Evidence that the stability of platelet aggregates depends on normal cytoskeletal assembly. Platelets 2009; 9:227-32. [PMID: 16793707 DOI: 10.1080/09537109876744] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Platelet activation is accompanied by changes in the composition of the platelet cytoskeleton with rapid incorporation and displacement of certain proteins. Here we have inhibited cytoskeletal assembly by pretreating platelets with cytochalasin D (CyD) and investigated the effect on the stability of the aggregates that form. The experiments were performed in both citrated and hirudinized platelet-rich plasma (PRP) and aggregation was induced by adenosine diphosphate (ADP), collagen, the TXA2-mimetic U46619 and adrenaline. Platelets in the aggregates that formed, underwent rapid disaggregation on addition of EDTA or a GpIIb-IIIa antagonist such as MK-852 and GR144053F, all of which are agents that interfere with the ability of fibrinogen to interact with GpIIb-IIIa. This was the case irrespective of the aggregating agent used and occurred in both citrated and hirudinized PRP. In contrast, the rate of disaggregation brought about by some other agents, iloprost and ARL 66096, appeared to be unaffected by CyD. Information was also obtained on the effects of CyD on the cytoskeletal changes brought about by ADP and the effects on the cytoskeleton of subsequent addition of M K-852. The results show that CyD retards the incorporation of certain proteins (actin, myosin, alpha -actinin, actin binding protein and a 66 K protein) into the cytoskeleton and that subsequent addition of MK-852 results in rapid displacement of some of these with re-incorporation of a 31 K protein. The results suggest that the early changes in the cytoskeleton following platelet activation contribute to the stability of the aggregates that form, and that interference with these early changes results in aggregates that are easily disassembled by agents that interfere with GpIIb-IIIa-fibrinogen complex formation.
Collapse
Affiliation(s)
- J A May
- University of Nottingham, UK
| | | | | | | | | | | |
Collapse
|
8
|
Manolopoulos P, Glenn JR, Fox SC, May JA, Dovlatova NL, Tang SW, Thomas NR, Ralevic V, Heptinstall S. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents. Platelets 2008; 19:134-45. [PMID: 18297551 DOI: 10.1080/09537100701708498] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
We have performed a detailed investigation of the effects on platelet function of coenzyme A (CoA) and several acyl-CoAs. Platelet aggregation was measured by turbidimetry and by platelet counting; platelet shape change was measured using light scattering; P-selectin, Ca2+ mobilization and vasodilator-stimulated phosphoprotein (VASP) phosphorylation were measured by flow cytometry. The compounds investigated inhibited ADP-induced platelet aggregation; those with saturated acyl groups containing 16-18 carbons were most effective. The effects of palmitoyl-CoA (16:0) were studied in depth. It inhibited platelet shape change and Ca2+ mobilization brought about by ADP (but not other agonists) indicating antagonism at P2Y(1) receptors, and also inhibited ADP-induced P-selectin expression. Effects of palmitoyl-CoA on the platelet aggregation and Ca2+ mobilization induced by several different agonists and agonist combinations were compared with those of MRS 2179 (a P2Y(1) antagonist) and AR-C69931 (a P2Y(12) antagonist), and were consistent with palmitoyl-CoA acting mainly at P2Y(1) but also with partial antagonism at P2Y(12) receptors. Antagonism at P2Y(12) receptors was confirmed in studies of VASP-phosphorylation. Palmitoyl-CoA did not act as an antagonist at P2X(1) receptors. The results are discussed in relation to the possibility that acyl-CoAs may contribute as endogenous modulators of platelet function and might serve as lead compounds for the design of novel antithrombotics.
Collapse
Affiliation(s)
- P Manolopoulos
- Centre for Integrated Systems Biology and Medicine, School of Medical and Surgical Sciences, Nottingham, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Platelet aggregation and microaggregate formation were measured in samples of stirred whole blood by flow cytometry. Blood samples were stirred in a multi-sample agitator with ADP, fixed and labelled with a platelet-specific CD42a-FITC fluorescent antibody. The blood was then diluted and applied directly to a flow cytometer. Platelets were identified using a gating procedure based on their expression of CD42a and then quantified. Aggregation was monitored as a fall in the number of single platelets. Both reversible and irreversible aggregation responses to ADP were determined and these were found to correlate directly with aggregation responses determined using a well-established single platelet counting technique using the Ultra-Flo 100 Whole Blood Platelet Counter. We found from flow cytometry that ADP-induced aggregation was coupled with a transient formation of platelet microaggregates over the initial 60 s following ADP addition. Assessment of single platelet loss by flow cytometry was found to be a reliable way of monitoring aggregation responses and provided new information on rapid microaggregate formation in ADP-stimulated blood.
Collapse
Affiliation(s)
- S C Fox
- Cardiovascular Medicine, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK.
| | | | | | | | | |
Collapse
|
10
|
Jones PM, May JA, Reitz JB, Solomon EI. Photoelectron Spectroscopic and Electronic Structure Studies of CH2O Bonding and Reactivity on ZnO Surfaces: Steps in the Methanol Synthesis Reaction. Inorg Chem 2004; 43:3349-70. [PMID: 15154797 DOI: 10.1021/ic035252q] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Adsorption of CH(2)O on ZnO(0001) has been investigated using XPS, NEXAFS, variable-energy photoelectron spectroscopy (PES), and density functional theory (DFT) calculations. CH(2)O is chemisorbed on the (0001) surface at 130 K. Its C1s XPS peak position at 292.7 eV and NEXAFS sigma shape resonance at 302.6 eV are consistent with an eta(1) bound surface geometry. Geometry optimized DFT calculations also indicate that CH(2)O is bound to the Zn(II) site in an eta(1) configuration through its oxygen atom. The variable-energy PES of the eta(1) bound CH(2)O/ZnO(0001) complex exhibits four valence band features at 21.2, 16.4, 13.8, and 10.7 eV below the vacuum level providing an experimental and theoretical description of this surface interaction. Annealing the ZnO(0001)/CH(2)O surface complex to 220 K decomposes the chemisorbed CH(2)O, producing formyl (291.5 eV), methoxide (290.2 eV), and formate (293.6 eV) intermediates. Thus this reaction coordinate involves the conversion of an oxygen bound formaldehyde to a carbon bound formyl species on ZnO(0001). Only formate is formed on the ZnO(100) surface. DFT is used to explore surface intermediates and the transition state in the methanol synthesis reaction (MSR). The bonding interactions of H(2), CO, CH(3)O(-), HCO(-), and trans-HCOH to the ZnO(0001) surface are elucidated using geometry optimization. H(2) was found to be heterolytically cleaved on the ZnO(0001) surface, and carbon monoxide, formyl, and methoxide are calculated to be eta(1) bound. These results are consistent with observed metal oxide surface reactivity where heterolytic bond cleavage is dominant. The oxygen atom in the bound formyl was found to be activated for attack by a proton. This results in the planar eta(1) bound trans-HCOH surface species. The transition state in the gas phase rearrangement of trans-HCOH to formaldehyde was calculated to have a barrier of 31 kcal/mol. The correlation diagram for this rearrangement in the gas phase indicates that configuration interaction at the crossing of two levels helps to lower the barrier. A transition state calculation was also performed for this rearrangement on the ZnO(0001) surface. The surface transition state geometry is significantly different than the gas phase. The surface geometry is no longer planar (23 degrees dihedral angle) and is displaced parallel to the surface. Interaction with the Zn(II) site at the crossing of surface bound CH(2)O and trans-HCOH levels further lowers the barrier to rearrangement relative to gas phase by 9 kcal/mol. The rearrangement of trans-HCOH (carbon bound) to CH(2)O (oxygen bound) on ZnO(0001) was calculated to be the overall barrier of the MSR reaction.
Collapse
Affiliation(s)
- P M Jones
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA
| | | | | | | |
Collapse
|
11
|
Affiliation(s)
- J A May
- Department of Anesthesiology, Medicine, the Medical College of Wisconsin, Milwaukee, 53226, USA
| | | | | | | | | |
Collapse
|
12
|
Natarajan P, May JA, Sanderson HM, Zabe M, Spangenberg P, Heptinstall S. Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function. Platelets 2000; 11:467-76. [PMID: 11177446 DOI: 10.1080/09537100020027842] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Platelets contain a well-developed and dynamic cytoskeleton composed mainly of actin and actin-associated proteins. Upon platelet activation there is rapid polymerisation of actin and a marked reorganisation of the platelet cytoskeleton. Cytochalasins are agents that interfere with the polymerisation of actin, and it has recently been discovered that cytochalasin H (CyH) is particularly effective as an inhibitor of the cytoskeletal reorganisation that occurs in platelets following activation by adenosine diphosphate (ADP). Here we have used CyH to inhibit platelet cytoskeletal reorganisation and to determine its effects on various aspects of platelet function. Experiments were performed in hirudinized platelet-rich plasma (PRP) or whole blood obtained from human volunteers. PRP was treated with 10 microM CyH or vehicle, then activated by ADP. The effect of CyH on cytoskeletal reorganisation was determined by SDS-PAGE of the Triton X-100 insoluble cytoskeletons and quantitated by densitometry. Platelet aggregation and aggregate stability in PRP were measured by monitoring changes in light absorbance; aggregation was measured in whole blood via platelet counting. Shape change, P-selectin expression and changes in intracellular calcium were measured using flow cytometry. CyH prevented the normal incorporation of actin, alpha-actinin and actin-binding protein into the cytoskeleton that occurred following ADP activation, and incorporation of myosin was markedly reduced. Aggregation was only partially inhibited but, more dramatically, the rate of disaggregation following addition of certain agents that interfere with fibrinogen binding to glycoprotein IIb/IIIa on the surface of platelets was markedly increased. The ADP-induced shape change was also inhibited. CyH had no effect on calcium mobilisation. Curiously, expression of P-selectin was potentiated by CyH, suggesting a modulatory role of the cytoskeleton in platelet secretory activity. The results suggest that cytoskeletal reorganisation plays an important role in platelet shape change and aggregation and contributes in a major way to the stability of the aggregates that form.
Collapse
Affiliation(s)
- P Natarajan
- Centre for Vascular Research, University of Nottingham, UK
| | | | | | | | | | | |
Collapse
|
13
|
Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110:925-34. [PMID: 11054084 DOI: 10.1046/j.1365-2141.2000.02208.x] [Citation(s) in RCA: 201] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Adenosine diphosphate (ADP) is an important platelet agonist and ADP released from platelet dense granules amplifies responses to other agonists. There are three known subtypes of ADP receptor on platelets: P2X(1), P2Y(1) and P(2T) receptors. Sustained ADP-induced aggregation requires co-activation of P2Y(1) and P(2T) receptors. AR-C69931MX, a selective P(2T) receptor antagonist and novel antithrombotic agent, was studied to characterize further the function of the P(2T) receptor. The roles of the P2Y(1) receptor and thromboxane A(2) were assessed using the selective P2Y(1) antagonist A2P5P and aspirin respectively. Aggregation was measured by whole blood single-platelet counting and platelet-rich plasma turbidimetry, using hirudin anticoagulation. Dense granule release was estimated using ([14)C]-5-hydroxytryptamine (HT)-labelled platelets. Ca(2+) mobilization, P-selectin expression, Annexin V binding and microparticle formation were determined by flow cytometry. P(2T) receptor activation amplified ADP-induced aggregation initiated by the P2Y(1) receptor, as well as amplifying aggregation, secretion and procoagulant responses induced by other agonists, including U46619, thrombin receptor-activating peptide (TRAP) and collagen, independent of thromboxane A(2) synthesis, which played a more peripheral role. P(2T) receptor activation sustained elevated cytosolic Ca(2+) induced by other pathways. These studies indicate that the P(2T) receptor plays a central role in amplifying platelet responses and demonstrate the clinical potential of P(2T) receptor antagonists.
Collapse
Affiliation(s)
- R F Storey
- Cardiovascular Medicine, University Hospital, Queen's Medical Centre, Nottingham, UK
| | | | | | | | | | | |
Collapse
|
14
|
Affiliation(s)
- A McHaourab
- Department of Anesthesiology, the Medical College of Wisconsin and the Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee 53226, USA
| | | | | | | |
Collapse
|
15
|
Chen HH, Gross S, Liao J, McLaughlin M, Dean T, Sly WS, May JA. 2H-Thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: synthesis, carbonic anhydrase inhibition and evaluation in the rabbit. Bioorg Med Chem 2000; 8:957-75. [PMID: 10882008 DOI: 10.1016/s0968-0896(00)00026-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Novel non-chiral 2H-thieno[3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides were synthesized for evaluation as potential candidates for the treatment of glaucoma. All of the compounds prepared were potent high affinity inhibitors of human carbonic anhydrase II, Ki < 0.5 nM. Additionally, inhibition of recombinant human carbonic anhydrase IV was determined for selected compounds; these were shown to be moderate to potent inhibitors of this isozyme with IC50 values ranging from 4.25 to 73.6 nM. Of the compounds evaluated for their ability to lower intraocular pressure in naturally hypertensive Dutch-belted rabbits, 5a, 17a3, 17b1, 17b2, 17h2 and 17i1 showed significant efficacy (> 20% decrease) in this model following topical ocular administration.
Collapse
Affiliation(s)
- H H Chen
- Ophthalmic Products Research, Alcon Research, Ltd., Fort Worth, TX 76134, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Halverson DO, Resau J, Faletto D, Fisher R, Anver M, Rong S, May JA, Tsarfaty I, Blair DG. A mouse fibroblast line cycles between monolayer and spheroid forms, regulates Met and HGF expression, and releases an attachment and growth-promoting substance. Cell Biol Int 1999; 23:257-74. [PMID: 10600235 DOI: 10.1006/cbir.1999.0346] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A subline of mesoderm-derived mouse NIH3T3 fibroblasts was selected for its ability to proliferate in serum-free media. This cell line (SFDH) grows as a monolayer at low density and spontaneously forms dense, multicellular spheroids at high density. Spheroid formation can also be induced by the addition of dexamethasone, polybrene, or heparin. Spheroids eventually detach from the substrate, but will reattach and re-form monolayers when transferred to fresh culture vessels and media, repeating the cycle again upon reaching high density. Thin section analysis of spheroids shows morphologically-distinct regions of cells, including an attenuated outer surface and a cuboidal interior with occasional lumen-like areas. Over time in culture, spheroids express increasing levels of met, the Met ligand-SF/HGF and cytokeratin, an epithelial marker, in comparison to monolayers. Both monolayer and spheroid-derived cells are rapidly tumorigenic in nude mice. Media conditioned by SFDH cells contain factors that stimulate growth and attachment of a variety of tumorigenic and non-tumorigenic cell lines, inducing cells to divide in serum-free media for up to 14 days when plated on tissue culture-treated and nontreated plastic surfaces pre-coated with SFDH conditional media. The growth-stimulating activity fractionates as a single peak over a sepharose column in the presence of 6 m urea, and sediments as a high molecular weight complex. Growth-stimulating activity can be neutralized by several antisera specific for hepatocyte growth factor, and the same sera recognize a novel approximately 37 kD protein in active supernatants. The cyclic, continuous nature of alternating monolayer and spheroid forms makes this cell line appropriate for studying changing gene expression patterns in progressive cell-cell/cell-matrix interactions.
Collapse
Affiliation(s)
- D O Halverson
- Intramural Research Support Program, SAIC Frederick, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702-1201, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost 1999; 82:1307-11. [PMID: 10544919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
We have used a whole blood single-platelet counting assay (WB-SPC) that is sensitive to microaggregation for monitoring GPIIb/IIIa antagonists and have compared this with other methodologies. In vitro effects of the GPIIb/IIIa antagonist fradafiban on ADP-induced platelet aggregation were determined using WBSPC and PRP turbidimetry, comparing citrate and hirudin anticoagulation. Fradafiban was a more potent inhibitor of aggregation assessed by PRP turbidimetry compared to WBSPC. Citrate showed only a trend towards enhancing fradafiban potency (p = 0.087). Citrated blood from 8 patients with unstable angina, randomised to receive oral lefradafiban (the oral prodrug of fradafiban) or placebo, was studied before and during treatment using WBSPC, PRP turbidimetry, impedance aggregometry and Rapid Platelet Function Assay (RPFA, Accumetrics). RPFA, PRP turbidimetry and WBSPC measurements correlated well. Impedance aggregometry responses were oversensitive to GPIIb/IIIa blockade. WBSPC was most discriminating at high levels of inhibition and offered a rapid means of monitoring GPIIb/IIIa antagonist effect within the therapeutic range of inhibition.
Collapse
Affiliation(s)
- R F Storey
- Division of Cardiovascular Medicine, University Hospital, Nottingham, UK.
| | | | | | | |
Collapse
|
18
|
Brown N, May JA, Wilcox RG, Allan LM, Wilson AM, Kiff PS, Heptinstall S. Comparison of antiplatelet activity of microencapsulated aspirin 162.5 Mg (Caspac XL), with enteric coated aspirin 75 mg and 150 mg in patients with atherosclerosis. Br J Clin Pharmacol 1999; 48:57-62. [PMID: 10383561 PMCID: PMC2014875 DOI: 10.1046/j.1365-2125.1999.00947.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
AIMS A new formulation, low dose microencapsulated aspirin, permits slow absorption of aspirin and presystemic acetylation of platelet cyclo-oxygenase within the portal circulation, potentially avoiding deleterious effects on gastric and systemic prostaglandin synthesis. The objective of this study was to determine whether the administration of microencapsulated aspirin was as effective as enteric coated (EC) aspirin as an inhibitor of platelet function in patients with atherosclerosis. METHODS One hundred and four patients were enrolled and randomised after a run in period of at least 14 days on aspirin EC 75 mg (day 0), to receive either microencapsulated aspirin 162.5 mg (n=34), aspirin EC 150 mg (n=36) or continue on aspirin EC 75 mg (n=34) for 28 days. Serum thromboxane B2 and collagen-induced platelet aggregation and release of 5-hydroxytryptamine (EC50 values) were measured on days 0 and 28. Aggregation/release EC50s were then repeated in the presence of a large dose of aspirin added in vitro to determine the EC50 at the maximum level of platelet inhibition. RESULTS Median thromboxane B2 levels were low after 14 days run-in therapy with aspirin EC 75 mg, but significant further reductions were seen on day 28 in patients randomised to microencapsulated aspirin 162.5 mg (P=0.0368) and aspirin EC 150 mg (P=0.0004) compared with those remaining on aspirin EC 75 mg. Median EC50 s on day 28 showed small but significant increases from baseline (day 0) in aggregation in patients randomised to microencapsulated aspirin 162.5 mg (0.62-0.85, P=0.0482) and in both aggregation and release in patients randomised to aspirin EC 150 mg (0.95-1.20, P=0.0002, 8.4-11.7, P<0. 0001, respectively) signifying enhanced antiplatelet activity. No changes were seen in patients continuing on aspirin EC 75 mg. Results following addition of high dose aspirin in vitro suggest that mechanisms other than thromboxane synthesis may be operative in the long term effects of microencapsulated aspirin 162.5 mg and aspirin EC 150 mg over aspirin EC 75 mg. CONCLUSIONS The results show good inhibition of thromboxane B2 synthesis and subsequent platelet activity by all preparations of aspirin, although both microencapsulated aspirin 162.5 mg and aspirin EC 150 mg are slightly more effective than aspirin EC 75 mg. A randomised trial is now required to determine whether microencapsulated aspirin is associated with fewer gastric side-effects.
Collapse
Affiliation(s)
- N Brown
- Cardiovascular Medicine, University of Nottingham, Nottingham NG7 2UH, UK
| | | | | | | | | | | | | |
Collapse
|
19
|
Boriack-Sjodin PA, Zeitlin S, Chen HH, Crenshaw L, Gross S, Dantanarayana A, Delgado P, May JA, Dean T, Christianson DW. Structural analysis of inhibitor binding to human carbonic anhydrase II. Protein Sci 1998; 7:2483-9. [PMID: 9865942 PMCID: PMC2143894 DOI: 10.1002/pro.5560071201] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
X-ray crystal structures of carbonic anhydrase II (CAII) complexed with sulfonamide inhibitors illuminate the structural determinants of high affinity binding in the nanomolar regime. The primary binding interaction is the coordination of a primary sulfonamide group to the active site zinc ion. Secondary interactions fine-tune tight binding in regions of the active site cavity >5 A away from zinc, and this work highlights three such features: (1) advantageous conformational restraints of a bicyclic thienothiazene-6-sulfonamide-1,1-dioxide inhibitor skeleton in comparison with a monocyclic 2,5-thiophenedisulfonamide skeleton; (2) optimal substituents attached to a secondary sulfonamide group targeted to interact with hydrophobic patches defined by Phe131, Leu198, and Pro202; and (3) optimal stereochemistry and configuration at the C-4 position of bicyclic thienothiazene-6-sulfonamides; the C-4 substituent can interact with His64, the catalytic proton shuttle. Structure-activity relationships rationalize affinity trends observed during the development of brinzolamide (Azopt), the newest carbonic anhydrase inhibitor approved for the treatment of glaucoma.
Collapse
Affiliation(s)
- P A Boriack-Sjodin
- Department of Chemistry, University of Pennsylvania, Philadelphia 19104-6323, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW. Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci 1998; 7:556-63. [PMID: 9541386 PMCID: PMC2143946 DOI: 10.1002/pro.5560070303] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Carbonic anhydrase IV (CAIV) is a membrane-associated enzyme anchored to plasma membrane surfaces by a phosphatidylinositol glycan linkage. We have determined the 2.8-angstroms resolution crystal structure of a truncated, soluble form of recombinant murine CAIV. We have also determined the structure of its complex with a drug used for glaucoma therapy, the sulfonamide inhibitor brinzolamide (Azopt). The overall structure of murine CAIV is generally similar to that of human CAIV; however, some local structural differences are found in the active site resulting from amino acid sequence differences in the "130's segment" and the residue-63 loop (these may affect the nearby catalytic proton shuttle, His-64). Similar to human CAIV, the C-terminus of murine CAIV is surrounded by a substantial electropositive surface potential that may stabilize the interaction with the phospholipid membrane. Binding interactions observed for brinzolamide rationalize the generally weaker affinity of inhibitors used in glaucoma therapy toward CAIV compared with CAII.
Collapse
Affiliation(s)
- T Stams
- Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia 19104-6323, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
May JA, Heptinstall S, Cole AT, Hawkey CJ. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. Thromb Res 1997; 88:183-92. [PMID: 9361371 DOI: 10.1016/s0049-3848(97)00229-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Platelet responses to several agonists and combinations of agonists have been measured in whole blood from healthy volunteers. We have determined the effects of once daily treatment for five days with plain aspirin 300 mg, plain aspirin 75 mg, enteric coated aspirin 300 mg or placebo. Measurements were made of platelet aggregation (using a platelet counting technique) and the release reaction (14C-5HT release from pre-labelled platelets). The extents of these responses before aspirin administration depended on the agonist used. ADP, adrenaline and PAF failed to induce any 14C-5HT release in most subjects, but combinations of these agonists acted synergistically to produce extensive 14C-5HT release. All three aspirin preparations reduced the extent of the platelet responses to most agonists: platelet aggregation induced by collagen, ristocetin and arachidonate and 14C-5HT release induced by collagen, streptokinase, and various combinations of ADP, adrenaline and PAF. None of the preparations had any effect on the aggregation that occurred in the absence of an agonist (spontaneous aggregation), but they all reduced streptokinase-induced aggregation to control (spontaneous) levels, and abolished the 14C-5HT release induced by arachidonate and by ristocetin. All three aspirin preparations were equally effective after two daily doses. No further inhibition of platelet responses was obtained after five daily doses. Plain aspirin 300 mg achieved its maximal effect after only a single dose, but enteric coated aspirin 300 mg (and sometimes plain aspirin 75 mg) produced sub-maximal inhibition after only a single dose. Parallel investigations on the effects of these aspirin regimes on gastric mucosal prostaglandin E2 synthesis and gastroduodenal mucosal injury were performed. These results will be reported separately.
Collapse
Affiliation(s)
- J A May
- Division of Cardiovascular Medicine, University Hospital, Nottingham, UK
| | | | | | | |
Collapse
|
22
|
May JA, Heptinstall S, Spangenberg P. Changes in the composition of the platelet cytoskeleton in response to ADP: effects of MK-852 and ARL 66096. Blood Coagul Fibrinolysis 1996; 7:221-4. [PMID: 8735824 DOI: 10.1097/00001721-199603000-00028] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Platelet activation by adenosine diphosphate (ADP) results in an alteration in the composition of the cytoskeleton. Here we have determined the effects of MK-852 and ARL 66096 on the cytoskeletal changes that occur. MK-852 is a GPIIb/IIIa antagonist that inhibits aggregation by interfering with fibrinogen binding ARL 66096 is a P2T antagonist that selectively inhibits ADP-induced aggregation. Neither agent inhibits the shape change response. Experiments were performed in hirudinized platelet-rich plasma. Platelet activation led to a significant and sustained increase in the cytoskeletal content of actin binding protein (ABP), myosin, alpha-actinin, a 66K protein and actin, and a significant decrease in a 31K protein. In the presence of MK-852 there was no increase in ABP or the 66K protein and no decrease in the 31K protein. The increase in myosin and alpha-actinin became reversible but there was still incorporation of actin into the cytoskeleton. In the presence of ARL 66096 there was no increase in ABP or the 66K protein and no decrease in the 31K protein. ARL 66096 also prevented incorporation of alpha-actinin and actin. As with MK-852, myosin incorporation became reversible. The results suggest that (1) myosin is incorporated into the cytoskeleton transiently during shape change, (2) ADP interaction with the ADP aggregation receptor (but not that for shape change) is associated with alpha-actinin and actin incorporation into the cytoskeleton, and (3) further changes that occur are consequent to fibrinogen binding and platelet aggregation.
Collapse
Affiliation(s)
- J A May
- Department of Medicine, University Hospital, Nottingham, UK
| | | | | |
Collapse
|
23
|
|
24
|
Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haemost 1995; 74:1310-5. [PMID: 8607115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Ticlopidine is thought to be a selective inhibitor of ADP-induced platelet function. Here we have investigated the effects of ticlopidine on platelet function in whole blood induced by ADP and by other platelet agonists. Whole blood was used because it was considered that ADP derived from red cells might act synergistically with other platelet agonists to enhance platelet responses, and that ticlopidine might interfere with this process. Measurements were performed using blood from 16 healthy volunteers before ticlopidine administration, after taking ticlopidine 250 mg daily for 10 days, after taking ticlopidine 250 mg twice daily for a further 10 days, and after 14 days off treatment. Ticlopidine proved to be a very effective inhibitor of the platelet aggregation induced by ADP; it was most effective in enhancing the reversibility of the aggregation response. The drug modestly but significantly reduced streptokinase, adrenaline, collagen, sodium arachidonate, PAF and U46619 - induced platelet aggregation. The drug significantly reduced the extent of the release reaction (14C-5HT release) induced by ADP, streptokinase, PAF, ristocetin and sodium arachidonate, and also reduced the extent of the synergistic 14C-5HT release induced by combinations of ADP and PAF, ADP and adrenaline and PAF and adrenaline. The various inhibitory effects of ticlopidine were evident after treatment with 250 mg daily but were more pronounced after 250 mg twice daily. All values had returned to normal after 14 days off treatment. Ticlopidine had no effect on serum thromboxane B2 production nor on several parameters of coagulation and fibrinolysis. We conclude that ticlopidine is an effective inhibitor of ADP-induced platelet aggregation and also the platelet aggregation and 14C-5HT release induced in whole blood by a number of platelet agonists and combinations of agonists. These latter effects are probably mainly via a selective effect on ADP. The inhibitory effects of the drug are dose-related.
Collapse
Affiliation(s)
- S Heptinstall
- University Hospital, Queen's Medical Centre, Nottingham, U.K
| | | | | | | | | | | |
Collapse
|
25
|
Armstrong R, May JA, Lösche W, Heptinstall S. Factors that contribute to spontaneous platelet aggregation and streptokinase-induced aggregation in whole blood. Thromb Haemost 1995; 73:297-303. [PMID: 7540774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
When whole blood is stirred there is a "spontaneous" platelet aggregation (SPA) which is presumed to be caused by proaggregatory factors released from platelets and other blood cells. Adding streptokinase (SK) to stirred whole blood frequently increases the rate and extent of the platelet aggregation that occurs; this is likely to be via immune complex formation between SK and natural anti-SK antibodies leading to increased release of pro-aggregatory factors. In this investigation we have examined the effects of several inhibitors and antagonists in an attempt to identify the proaggregatory factors that contribute to both SPA and SK-induced aggregation (SKA) and to evaluate different means of inhibiting both processes. The effects of the inhibitors/antagonists were determined in vitro after adding them to citrated whole blood obtained from healthy volunteers. Platelet aggregation was measured using a platelet counting technique. Inhibition of both SPA and SKA by apyrase and by FPL 66096 (a P2T receptor antagonist) demonstrated the involvement of ADP in both processes. Inhibition by chlorpromazine indicated that the most likely source of the ADP is red cells. The effects of sulotroban (a TXA2 antagonist) indicated involvement of TXA2 in SKA but not in SPA. The lack of effect of specific antagonists at S2, alpha 2 and PAF receptors suggested lack of involvement of serotonin, catecholamines and platelet-activating factor in either SPA or SKA. Both SPA and SKA were potently inhibited by low concentrations of iloprost (a PGI2 analogue), but a high concentration of SIN-1 (a NO donor) was much less effective.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R Armstrong
- Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham, UK
| | | | | | | |
Collapse
|
26
|
Abstract
OBJECTIVE To determine the optimum conditions for the demonstration of an antiplatelet effect of nitric oxide and to use these conditions to elucidate the effects of a transdermal glyceryl trinitrate patch on platelet aggregation in normal volunteers. METHODS An open prospective crossover study. The effects of nitric oxide on platelet aggregation in whole blood and platelet rich plasma as stimulated by adenosine diphosphate and U46619 was assessed in the presence and absence of iloprost and MB22948. Optimum conditions for the demonstration of an antiplatelet effect of nitric oxide were then applied to whole blood from normal volunteers in the presence and absence of a transdermal glyceryl trinitrate patch. SETTING University hospital. SUBJECTS Eight normal volunteers. MAIN OUTCOME MEASURES Platelet aggregation in the presence and absence of transdermal glyceryl trinitrate. RESULTS The optimum conditions for the demonstration of an antiplatelet effect of nitric oxide in whole blood were collecting blood into a tube containing MB22948 and citrate and stimulating platelet aggregation with adenosine diphosphate in the presence or absence of iloprost. Using this method a significant effect of transdermal glyceryl trinitrate on platelet aggregation was shown (P < 0.03) in the presence and absence of iloprost. CONCLUSIONS These results are consistent with an inhibitory effect on platelet aggregation of nitric oxide liberated by transdermal glyceryl trinitrate. Optimum test conditions are needed to show this effect. The clinical significance of the antiplatelet effect of transdermal glyceryl trinitrate is unknown.
Collapse
Affiliation(s)
- R Andrews
- Department of Medicine, University Hospital, Queen's Medical Centre, Nottingham
| | | | | | | |
Collapse
|
27
|
Canellakis ZN, Bondy PK, May JA, Myers-Robfogel MK, Sartorelli AC. Identification of a glycosidase activity with apparent specificity for 2-deoxy-D-glucose in glycosidic linkage. Eur J Biochem 1984; 143:159-63. [PMID: 6468386 DOI: 10.1111/j.1432-1033.1984.tb08354.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
2-Deoxy-D-glucose (dGlc) is a carbohydrate with significant activity as an inhibitor of glucose metabolism and as a precursor in the synthesis of glycosylated macromolecules; several of the enzymes associated with its metabolism remain uncharacterized. In the present report, the partial purification and some of the properties of a mammalian enzyme that appears to be relatively specific for the hydrolysis of dGlc bound in glycosidic linkage is described. The physiological function of this enzymatic activity is unknown. In addition, dGlc has been shown to be taken up by HTC cells in culture and incorporated into macromolecular bound form, both as dGlc and as 2-deoxygalactose which is formed from dGlc.
Collapse
|
28
|
Shiba DA, May JA, Sartorelli AC. Relationship of spontaneous chemical transformation of arylsulfonylhydrazones of 2-pyridinecarboxaldehyde 1-oxide to anticancer activity. Cancer Res 1983; 43:2023-9. [PMID: 6831433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The arylsulfonyl-hydrazones of 2-pyridinecarboxaldehyde 1-oxide represent a relatively new class of antineoplastic agents with the potential for clinical usefulness. The requirement for spontaneous chemical transformation of these agents to exert anticancer activity was evaluated using as the prototype the most potent member of this class synthesized to date, the 3,4-dimethoxybenzene sulfonylhydrazone of 2-pyridinecarboxaldehyde 1-oxide (3,4-DSP. 3,4-DSP was chemically unstable, decomposing with a half-life of 19 min in 0.01 M potassium phosphate buffer (pH 7.4) at 37 degrees. The major chemical decomposition product was identified as 2-pyridylcarbinol 1-oxide by comparison with the authentic compound. This carbinol is hypothesized to be formed via the intramolecular abstraction of hydrogen from the arylsulfonyl-hydrazone, a process that leads to the release of 3,4-dimethoxybenzenesulfinic acid and the formation of 1-oxidopyridin-2-yldiazomethane, which subsequently reacts with water. The diazomethane intermediate is a potent alkylating agent which, if generated in cells, would have the potential to alkylate nucleophilic groups of biologically important macromolecules. The proposed reactive species was trapped using both 4-(4-nitrobenzyl)pyridine (NBP) and morpholine, and the latter product was characterized by mass spectroscopy. The importance of the chemical formation of an alkylating species to cytotoxicity was demonstrated by studies in which solutions of 3,4-DSP were "aged" prior to addition to L1210 leukemia cells in culture and prior to incubation with NBP. The "aging" of 3,4-DSP for 20 min resulted in a 4-fold decrease in cytotoxicity, and aging for 1 to 3 hr led to complete loss of cytotoxicity. Correspondingly, a 20-min aging period decreased alkylation of NBP by 51%, and 3-hr aging resulted in essentially no alkylation of the nucleophile. Further support for the above proposed chemical activation pathway was provided by correlations between in vitro cytotoxicity, in vivo antineoplastic activity, chemical stability, and the degree of alkylation of NBP by a wide variety of arylsulfonyl-hydrazones. The lack of the 1-oxide, envisioned to be required for intramolecular hydrogen abstraction, the steric prevention of the abstraction, or the replacement of the proton of the nitrogrn of the side-chain by a methyl group resulted in a marked increase in chemical stability and a corresponding loss of the ability to alkylate NBP and to inhibit the replication of L1210 leukemia cells in culture.
Collapse
|
29
|
May JA. Caring for terrazzo. Exec Housekeeper 1979; 26:29. [PMID: 10243403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
30
|
Abstract
6-Substituted 6-deoxy-L-galactose (L-fucose) derivatives were synthesized as potential antimetabolites of L-fucose. The cytotoxic effects of these compounds were evaluated on P388 leukemia cells in culture. The L-fucose analogues which showed the most potent growth inhibition were the sulfonyl ester, bromo, and iodo derivatives; since these compounds were all capable of alkylation, it is conceivable that their cytotoxic action is a consequence of this property. In agreement with this interpretation, none of the agents synthesized showed specific inhibition of the incorporation of L-[3H]fucose into glycoprotein.
Collapse
|
31
|
May JA, Sartorelli AC. Antineoplastic properties of arylsulfonylhdrazones of 3-formylpyridazine 2-oxide and 4-formylpyrimidine 3-oxide. J Med Chem 1978; 21:1333-5. [PMID: 722747 DOI: 10.1021/jm00210a036] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The antineoplastic activity of several arylsulfonylhydrazones of 4-formylpyrimidine 3-oxide and of 3-formylpyridazine 2-oxide has been investigated. Derivatives of the latter heteroaromatic N-oxide showed excellent antineoplastic potency against the murine neoplasm Sarcoma 180 but were inactive against leukemia L1210. In contrast, derivatives of 4-formylpyrimidine 3-oxide were inactive against both of these transplanted tumors.
Collapse
|
32
|
May JA, Sage BH. Spinner films for reticulocyte counts. Am J Med Technol 1976; 42:357-60. [PMID: 984074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The widely practiced method for performing a reticulocyte count includes counting 1000 normal erythrocytes while searching for a relatively small population of reticulocytes. A method is presented using a spinner reticulocyte preparation which avoids the need to count the normal erythrocytes, thereby eliminating most of the tedium from the test. The accuracy and reproducibility of this new method, as compared to the currently practiced method, is presented, along with the results of an on-line comparison.
Collapse
|
33
|
May JA, Townsend LB. Synthesis of V-triazolo(4,5-c)pyridine nucleosides and 4-(beta-D-ribofuranosyl)amino-1,2,3-thiadiazolo(5,4-b)pyridine via a rearrangement. J Org Chem 1976; 41:1449-56. [PMID: 1263007 DOI: 10.1021/jo00870a035] [Citation(s) in RCA: 29] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
34
|
May JA. First signs of anaphylaxis. West J Med 1975; 123:371. [PMID: 18747574 PMCID: PMC1129913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|